Avid Bioservices Inc (CDMO)

[swg_tdr]

txs Hutschi. developments leave us in the dust

Keytruda's progress came as a surprise to many investors. Although Merck presented good results from a small trial in October, it had been widely thought that data from a larger Phase III combination study would also be needed.
Frazier said that the early filing reflected the fact that the treatment effect was "pretty remarkable".

Remarkable, so where is our chemo plus Bavi Phase 3 or its 30% sectorfavorable patient outcome and follow-up with a decisions to partner -- forget all about AVID

Many experts previously assumed that combinations of two expensive immuno-oncology (I-O) drugs from AstraZeneca AZN.L and Bristol-Myers Squibb BMY.N would be approved before chemotherapy ones for fighting lung cancer.
"That doctors can do it at a price point that is lower than a combination of two I-O agents is a benefit to the healthcare system," Frazier said.

best,
N